Zhuzhou Qianjin Pharmaceutical(600479.SH): Fuke Qianjin Capsule/Tablet selected as one of the first 100 Traditional Chinese Medicine varieties based on evaluative evidence.

According to Zhuzhou Qianjin Pharmaceutical's announcement, the company's Chinese Traditional Medicine Evidence-based Medicine Center has released a notice regarding the publication of 100 kinds of traditional Chinese medicines based on evaluated evidence. The company's products, Zhuzhou Qianjin Capsules/Tablets for gynecology, have been selected as one of the first 100 traditional Chinese medicines based on evaluated evidence. It is reported that the company's core product, Zhuzhou Qianjin Capsules/Tablets for gynecology, is an exclusive national essential drug and a national medical insurance Class A variety. The main ingredients of the product include Radix Rubiae Cordatae, Rhizoma Belamcandae, Radix Polygoni Multiflori Preparata, Rhizoma Drynariae, Caulis Spatholobi, Radix Angelicae Sinensis, Herba Cistanches, and Radix Codonopsis, which have the effects of clearing heat, eliminating dampness, nourishing qi, and promoting blood circulation. It is used for leukorrhea, abdominal pain caused by damp-heat stagnation, with symptoms such as excessive leucorrhea, thick and yellowish, foul-smelling, lower abdominal pain, lumbosacral soreness, and fatigue; chronic pelvic inflammatory disease, endometritis, and chronic cervicitis with the above symptoms. The inclusion of Zhuzhou Qianjin Capsules/Tablets for gynecology in the first batch of 100 traditional Chinese medicines based on evaluated evidence has increased the company's competitiveness and is beneficial for the market promotion of this product, enhancing the company's brand awareness. However, the impact on the company's business performance cannot be estimated at the moment. Investors are advised to pay attention to investment risks.